Lantern Pharma Completes Japan Enrollment for Phase II LP-300 NSCLC Trial Ahead of Schedule

Clinical TrialsTherapueticsFDA
Written By Corey Hubbard
Lantern Pharma Completes Japan Enrollment for Phase II LP-300 NSCLC Trial Ahead of Schedule
Glassbury Team

GlassBury Cares Podcast

Episode #31

Corey Hubbard
Previous

Pfizer's Sickle Cell Strategy Stumbles: Inclacumab Fails Phase III Oxbryta Withdrawn
Next

Brain Breakthrough: Oragenics and Southern Star Pioneer New Hope for Concussion Treatment